Anjali Singh

Skoda targets profitable India growth, weighs CNG and niche diesel return

Evaluates India-made electric SUV as it deepens localisation, expands its retail network beyond 200 locations and looks to widen its customer base in smaller markets

Mahindra targets 5% heavy truck share, plans to add 15 dealerships

The company plans to expand its dealership network and leverage SML Mahindra as it targets higher market share in key heavy truck segments

Tata Motors Q1 profit jumps 83% on strong CV demand, flags price hikes

The commercial vehicle maker reported a net profit of Rs 2,560 crore as volumes rose 26 per cent, but commodity inflation weighed on margins and prompted price increases

Policy support, lower costs to lift e-bus penetration to 30% by FY30: Icra

Electric buses offer lower ownership costs than diesel and CNG models, while government schemes and payment-security reforms are expected to accelerate adoption

Higher costs drag Zydus Lifesciences' Q1 profit down 36%; revenue rises 22%

Revenue from operations rose 22 per cent to Rs 8,017 crore, led by India formulations, consumer wellness and international markets, while EBITDA margin contracted

Scooter sales outpace motorcycles as GST cuts, EV boom reshape 2W market

Scooter sales outpaced motorcycles in Q1FY27 as EV adoption, lower GST, affordability and changing commuting preferences boosted demand across the segment

Bharat Forge posts ₹89.7 cr Q1 loss, retains 20-25% India growth outlook

Bharat Forge reported an Rs 89.7 crore consolidated net loss after restructuring charges at its German subsidiary, while revenue from operations rose 18.7 per cent

Maruti Suzuki posts record sales, eyes faster path to next million vehicles

Maruti Suzuki expects small-car revival, new SUVs, capacity expansion and record exports to help it reach its next million-vehicle sales milestone sooner than anticipated

EV retail sales hit record high in July as adoption gathers pace

EV retail sales rose 66 per cent year-on-year to 327,901 units in July, pushing penetration to nearly 12 per cent as adoption accelerated across vehicle segments.

JK Tyre sees double-digit FY27 revenue growth despite input cost pressure

Robust domestic demand from original equipment manufacturers and the replacement market is expected to support growth, even as elevated input costs continue to weigh on margins

Biocon eyes stronger H2FY27 growth on back of recent US product launches

Biocon expects momentum to strengthen in H2FY27, driven by new US biosimilar and generic launches, improved operating leverage and a favourable product mix

International business to remain key driver for Emcure Pharma in FY27

Emcure expects overseas markets to drive growth in FY27 through product approvals, differentiated offerings and capacity expansion, while domestic business is seen improving

Eisai launches Alzheimer's drug Leqembi in India after CDSCO approval

The disease-modifying therapy for early Alzheimer's disease will cost ₹21,682 per vial, with treatment expenses varying according to patients' weight and dosage

OPPI seeks India-based start for regulatory data protection period

Industry body says it is open to a shorter regulatory data protection period if the clock starts from a drug's marketing approval in India rather than its first global approval

Sun Pharma Q1 profit rises 27%; US generics remain under pressure

Sun Pharma reported a 27 per cent rise in Q1FY27 profit, driven by India and innovative medicines, while weakness in the US generics business continued to weigh on growth

Piramal Pharma eyes mid-teens growth in FY27, prioritises organic expansion

Higher capacity utilisation, operating leverage and broad-based demand across CDMO, hospital generics and consumer healthcare are expected to support margins in FY27

As uncertainty becomes the new normal, M&M must enter attack mode: Mahindra

Mahindra Group chairman says prolonged global uncertainty offers prepared companies an edge, with India poised to emerge as a multi-aligned 'connector economy'

ChrysCapital acquires Novartis India, appoints Vikas Gupta as CEO

The private equity firm has taken control of the BSE-listed drugmaker, appointed Vikas Gupta as CEO and plans to build a branded generics platform in India

Sun Pharma to launch semaglutide in Brazil with Hypera Pharma soon

Sun Pharma will launch the once-weekly diabetes treatment through Hypera Pharma as generic competition intensifies in Brazil's $413 million semaglutide market

L&T bets ₹5,000 crore to become Tier-1 supplier in auto electronics market

Engineering major will invest over five years in EV motors, ADAS and connected-vehicle technologies, targeting a fast-growing market dominated by global players